NGL Fine-Chem Limited (NSE:NGLFINE)
2,913.40
+83.00 (2.93%)
Sep 24, 2026, 2:44 PM IST
NGL Fine-Chem Revenue
NGL Fine-Chem had revenue of 1.39B INR in the quarter ending June 30, 2026, with 33.57% growth. This brings the company's revenue in the last twelve months to 5.36B, up 40.41% year-over-year. In the fiscal year ending March 31, 2026, NGL Fine-Chem had annual revenue of 5.01B with 36.03% growth.
Revenue (ttm)
5.36B
Revenue Growth
+40.41%
P/S Ratio
3.28
Revenue / Employee
10.76M
Employees
498
Market Cap
17.59B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 5.01B | 1.33B | 36.03% |
| Mar 31, 2025 | 3.68B | 295.68M | 8.73% |
| Mar 31, 2024 | 3.39B | 606.08M | 21.79% |
| Mar 31, 2023 | 2.78B | -394.22M | -12.42% |
| Mar 31, 2022 | 3.18B | 595.28M | 23.08% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Marksans Pharma | 31.72B |
| Pfizer | 25.70B |
| Rubicon Research | 19.36B |
| CORONA Remedies | 14.79B |
| Sanofi Consumer Healthcare India | 9.50B |
| SMS Pharmaceuticals | 8.98B |
| Senores Pharmaceuticals | 6.80B |
| Sai Parenteral's | 5.26B |